Endostatin a Potential Biomarker for Heart Failure with Preserved Ejection Fraction by Barroso, Michael Coll et al.
Original Article
Endostatin a Potential Biomarker for Heart Failure with Preserved 
Ejection Fraction
Michael Coll Barroso,1* Philip Boehme,2* Frank Kramer,2 Thomas Mondritzki,3 Till Koehler,4 Jan-Erik Gülker,5 Martin 
Karoff,1 Wilfried Dinh2
Klinik Königsfeld der Deutschen Rentenversicherung Westfalen in Ennepetal (NRW) – University Hospital;1 Bayer AG - Drug Discovery – 
Experimental Medicine;2 Bayer AG – Drug Discovery – Therapeutic Research Groups Cardiovascular III;3 Department of Cardiology – HELIOS 
Clinic Wuppertal – University Hospital Witten/Herdecke;4 Department of Cardiology - HELIOS Clinic Krefeld5
* Contribute equally to this work
Mailing Address: Wilfried Dinh •
Aprather Weg 18ª, 42113, Wuppertal
E-mail: wilfried.dinh@bayer.com, wilfried.dinh@gmail.com
Manuscript received April 06, 2017, revised manuscript July 04, 2017, 
accepted July 24, 2017
DOI: 10.5935/abc.20170144
Abstract
Background: Endostatin is a circulating endogenous angiogenesis inhibitor preventing neovascularization. Previous studies 
demonstrated the prognostic value of Endostatin among patients with heart failure with reduced ejection fraction (HFrEF). 
However, the role of Endostatin among patients with heart failure with preserved ejection fraction (HFpEF) remains unclear.
Objective: This study aimed to investigate the association between serum Endostatin levels, natriuretic peptide levels 
and the severity of left ventricular diastolic dysfunction and the diagnosis of HFpEF.
Methods: Endostatin serum concentrations were measured in 301 patients comprising 77 HFpEF patients, 169 patients 
with asymptomatic left ventricular diastolic dysfunction (ALVDD), and 55 controls with normal cardiac function.
Results: Endostatin serum levels were significantly elevated in patients with HFpEF (median/interquartile range 179.0 
[159-220]) and ALVDD (163.8 [145.4-191.3]) compared to controls (149.1 [130.6-176.9]), p < 0.001 and p = 0.004, 
respectively) and significant correlated with N-terminal pro B-type natriuretic peptide (NT-proBNP).
Conclusions: This hypothesis-generating pilot study gives first evidence that Endostatin correlates with the severity of 
diastolic dysfunction and may become a novel biomarker for HFpEF. We hypothesize a rise in Endostatin levels may reflect 
inhibition of adaptive angiogenesis and adverse cardiac remodeling. (Arq Bras Cardiol. 2017; 109(5):448-456)
Keywords: Heart Failure; Endostatins; Natriuretic Peptides; Biomarkers; Stroke Volume.
Introduction
The patient population affected by heart failure (HF) is 
growing in a constant manner. This is because of an aging 
society, western lifestyle and improved acute clinical care 
(e.g. after myocardial infarction).1 Although, the treatment of 
chronic conditions improved over the last decades, mortality 
and morbidity rates in this patient population are amongst 
the highest for western healthcare systems.2 In the United 
States (US) HF is the leading cause for hospitalization for 
patients older > 65 years of age.3 In 2030 the direct costs 
for heart failure will reach 70 billion US$ in the US alone.4 
Half of the patients affected by HF present with a diastolic 
dysfunction and a preserved ejection fraction (HFpEF), with 
this proportion increasing.5 Clinical data proves that those 
patients suffering from a reduced ejection fraction (HFrEF) 
show better outcomes compared to HFpEF patients.6-8 
A reason might be that no therapy has been shown to improve 
outcomes in HFpEF.9 Current therapeutic options including 
fluid management, blood pressure control and physical 
exerciseto relief patients’ symptoms. A major drawback 
regarding the development of new therapies for HFpEF, is 
the absence of clear diagnostic criteria.10 This makes the 
definition of patient populations for clinical studies difficult. 
At present, the diagnosis is solely based echocardiography. 
Especially, the separation between HFpEF and HFrEF is 
even more challenging and misleading in patients with 
newly diagnosed HF.11 Therefore new strategies for disease 
phenotyping in HF are urgently needed. New biomarkers 
may achieve better disease phenotyping.12 Although, many 
reports have been published on HF biomarkers over the 
last decades, the impact on clinical decision making is still 
limited.13 BNP/NTproBNP demonstrated high clinical utility 
to identify patients at high risk for heart failure hospitalization 
and death. However, in this context these markers for clinical 
studies are only applicable in relatively stable patients and 
not in terminal HF patients. Furthermore, the use of BNP/
NTproBNP in clinical practice to optimize therapy with 
drugs, which are known to improve patient`s outcome is 
suitable.14 However, BNP/NTproBNP is not accepted as 
surrogate endpoint and can only exploratorily be used as 
endpoint in clinical trials. The appraisal of clinical utility of 
BNP/NTproBNP manifests in the current guidelines for the 
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propose Endostatin, a potent angiogenesis inhibitor, known 
mostly from oncology, as a potential new HF biomarker 
candidate.16-18 Most importantly Gouya et al. reported in a 
prospective observational cohort study in 151 HF patients, 
a correlation between elevated circulating Endostatin levels 
and mortality. Furthermore, this study showed a clear 
association between Endostatin levels and progressing 
diastolic dysfunction, the key characteristic of HFpEF.19 
This is why we hypothesize that Endostatin could potentially 
be a biomarker suitable to diagnose and disease phenotype 
HFpEF patients. In the present study, we aimed to investigate 
the sole role of Endostatin as a biomarker for HFpEF and 
diastolic dysfunction.
Methods
The study protocol was approved by the Ethics Committee 
of the Private University of Witten/Herdecke, Germany 
(project n°. 91/08) and conducted in accordance with the 
Declaration of Helsinki. Signed written informed consent was 
obtained from all patients.
Study population
Participants of the prospective observational cohort study 
were patients contacting the HELIOS Klinikum Wuppertal Heart 
Center (Wuppertal, Germany) for elective coronary angiography 
or diagnostic work-up of heart failure. Patients with a stable or 
suspected coronary artery disease (CAD) and/or a diagnostic 
workup of CHF were included in the study. The exclusion criteria 
were: left ventricular ejection fraction (EF) < 50%, known CAD 
with progressive chest pain within the last month, coronary 
angioplasty or myocardial infarction within 6 weeks, hypertrophic 
cardiomyopathy, moderate-to-severe valvular heart disease, 
uncontrolled hypertension, atrial fibrillation or other severe 
arrhythmias, serum-creatinine > 2,0 mg/dl. Patients selected for 
the control group had to have no history or symptoms of CHF, 
a normal ejection fraction > 55%, a ratio of the early diastolic 
transmitral velocity (E) and the early diastolic tissue Doppler 
velocity (E´) of < 8, and normal NTproBNP values. A total of 
301 patients were recruited and assigned to three groups based 
on echocardiographic diagnostic criteria as recommended by the 
European Society of Cardiology.20 The control group consisted 
of 55 patients (29 males) with normal diastolic function (DF). 
The group with asymptomatic left ventricular diastolic 
dysfunction (ALVDD) contained 169 patients (95 males) with 
E medial < 8 cm/s, E/E’ medial ratio 8-15 and NT-proBNP levels 
< 220 pg/ml. The group with HFpEF comprised 77 patients 
(46 females, 31 males) displaying ALVDD Grad II - III with 
E/E´ratio > 15, NT-proBNP levels > 220 pg/mL and current or 
previous signs or symptoms of heart failure. 
Echocardiography
Echocardiography was performed using a standard 
ultrasound system (Vivid 7, General Electric, Milwaukee, 
Wisconsin). A complete transthoracic study was performed 
including 2D, M-mode, spectral and colour Doppler techniques 
following current recommendations and guidelines.21,22 
The left atrium volume index (LAVI) was calculated using the 
biplane area-length method. Left ventricular EF was measured 
by means of the modified biplane Simpson’s method.23 
Left ventricular mass index (LVMi) was computed with the 
Devereux formula indexed to the body surface.22 HFpEF was 
defined in accordance with the EAE/ASE recommendation, 
based on the assessment of left ventricular diastolic function.24 
Primary measurements included mitral inflow peak early 
(E-wave) and late (A-wave) diastolic filling velocities as well 
as systolic (S) and early diastolic (E’) mitral annular velocities 
whereat in each case three consecutive beats were measured 
and averaged. Conventional transmitral flow was measured 
with Pulse-waved Doppler (PW). PW tissue Doppler imaging 
(DTI) was performed at the junction of the septal and lateral 
mitral annulus in the apical 4-chamber view. Based on primary 
measurements E/A and E/E’ ratios were calculated.
Laboratory analysis
Peripheral venous whole blood samples were taken after 
5 minutes at rest for routine laboratory testing (OGTT, total 
cholesterol, LDL cholesterol, HDL cholesterol, triglyceride, 
creatine, leucocytes, hemoglobin, creatin kinase, TSH, hsCRP, 
GOT, GPT). Blood was drawn into pyrogen-free tubes without 
any additives, centrifuged at room temperature, aliquoted and 
stored at –80°C. All laboratory analysis were outsourced to Roche 
Diagnostics (Penzberg, Germany) and performed on blinded 
samples. For analysis of plasma NT-proBNP the Elecsys 2010 
NT-proBNP assay (Roche Diagnostics, Mannheim, Germany) 
was used. For measurement of Endostatin the ELISA assay of 
R&D Systems (Minneapolis, MN USA) was used. All assays were 
performed according to manufacturer’s recommendations.
Statistical analysis
All analyses were performed using SPSS statistical software 
(SPSS 19.0, Chicago, IL, USA). The data are presented 
as median with 25th/75th percentiles (interquartile range) 
for continuous variables or as absolute numbers and 
corresponding percentages for categorical variables unless 
otherwise specified. Log transformed values were used for 
analysis as appropriate. A p-value < 0.05 was considered 
statistically significant. We used the Kolmogorov-Smirnov 
test as appropriate to test for normal distribution. 
The Mann-Whitney U-test was used to analyze differences 
between the medians of two groups and the Kruskal-Wallis 
test to test the equality of medians among more than two 
distinct groups. Fisher’s Test was used for the comparison 
of two sets of binary variables and the χ2 test to evaluate 
differences in proportions in more than 2 sets of categorical 
variables. Endostatin and NT-proBNP levels were compared 
across subjects with normal diastolic function, mild 
ALVDD and HFpEF by the Mann-Whitney U-test, and 
Jonckheere-Terpstra test. Spearman rank correlation was 
used to identify variables associated with Endostatin. 
A multivariable model was included to predict the presence 
of HFpEF and included the following covariates: Endostatin, 
age, gender, diabetes, hypertension, coronary artery disease 
and body mass index. Due to the exploratory nature of this 
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Table 1 – Baseline characteristics of the study population. Values are median (25-75interquartile range) or absolute numbers and percentage (%)
Clinical variables
(median/interquartile range or %)
Studied patient groups
p value
Control (n = 55) mild ALVDD (n = 169) HFpEF (n = 77)
Age (years) 54 (48-61) 66 (58-71) 73 (68-77) < 0.001*
BMI (kg/m2) 25.5 (24.1-29.1) 27.8 (25.6-32.3) 27.5 (25.7-32.0) 0.001*
Waist circumference (cm) 98 (86-107) 102 (94-114) 102 (98-111) 0.002*
Hip circumference (cm) 98 (94-103) 103 (96-111) 105 (98-114) 0.003*
Systolic BP (mmHg) 125 (110-136) 134 (127-140) 136 (130-140) 0.001*
Diastolic BP (mmHg) 80 (70-80) 80 (76-84) 80 (72-84) 0.12
Resting HR (beats/min) 70 (68-76) 72 (69-76) 70 (65-76) 0.51
CAD, n (%) 21 (38,2) 99 (58,6) 49 (63,6) 0.009*
CABG, n (%) 1 (2.0) 5 (3.0) 9 (11.7) 0.007*
PCI, n (%) 15 (27.3) 75 (44.4) 33 (42.9) 0.074
History of MI, n (%) 8 (14.5) 36 (21.3) 17 (22.1) 0.501
History of stroke, n (%) 1 (2.0) 5 (3.0) 3 (3.9) 0.824
Cardiovascular risk factors
Treated hypertension, n (%) 38 (69.1) 148 (88.1) 73 (96.1) < 0.001*
Diabetes mellitus, n (%) 4 (7.3) 45 (26.6) 22 (28,6) < 0.001*
Medication
ACE inhibitor, n (%) 26 (47.3) 110 (65.1) 42 (54.5) 0.042*
AT1 receptor blocker, n (%) 6 (10.9) 17 (10.1) 23 (29.9) < 0.001*
Diuretics, n (%) 8 (14.5) 45 (26.6) 36 (49.8) < 0.001*
Ca2 blocker, n (%) 6 (10.9) 23 (13.6) 21 (27.3) 0.013*
Β-blocker, n (%) 28 (50.9) 103 (60.9) 57 (74.0) 0.021*
*statistically significant (p < 0.05). BMI: body mass index; BP: blood pressure; HR: heart rate; CAD: coronary artery disease; CABG: coronary artery bypass graft; 
PCI: percutaneous coronary intervention; MI: myocardial infarction; DF: diastolic function; ALVDD: left ventricular diastolic dysfunction; HFpEF: heart failure with 
preserved ejection fraction; NS: non-significant. The Mann-Whitney U-test was used to analyze differences between the medians of two groups and the Kruskal-Wallis 
test to test the equality of medians among more than two distinct groups.
Results
Study population characteristics
Table 1 provides an overview of the clinical characteristics 
of all 301 patients included in our study. The three groups 
showed comparable diastolic blood pressure, resting heart 
rate and history of myocardial infarction and stroke. Patients 
with mild ALVDD or HFpEF were older, more obese, had a 
higher systolic blood pressure on average and showed a higher 
prevalence of comorbidities including CAD and coronary 
artery bypass graft, as well as cardiovascular disease risk. In 
addition, treatments varied across groups.
Endostatin and diastolic function
Table 2 summarizes the laboratory data and echocardiographic 
function parameter stratified by the study groups HFpEF vs. 
ALVDD vs. controls. Levels of Endostatin were 179.0 [159-220] 
ng/mL in HFpEF, 163.8 [145.4-191.3] ng/mL in ALVDD and 
149 [130.6 - 176.9] ng/mL in the control group, respectively 
(Figure 1A). Serum levels of Endostatin were significantly higher 
in patients with HFpEF (p < 0.001) and mild ALVDD (p = 0.001; 
Table 2) compared to individuals from the control group. 
Furthermore, Endostatin serum concentration was elevated 
in patients with mild ALVDD compared to asymptomatic 
controls with normal diastolic and systolic function (p = 0,004). 
In addition, there was a significant association between 
increasing Endostatin quartiles and higher NT-pro-BNP levels. 
No clinically relevant differences were observed in the clinical 
routine laboratory assessments. In multivariable analysis included 
the covariates Endostatin, age, gender, diabetes, hypertension, 
coronary artery disease and body mass index, age (p < 0.001) 
and Endostatin (p = 0.008 were independently associated 
with HFpEF
Association of Endostatin levels with cardiac structure  
and function
Increasing quartiles of Endostatin were significantly 
associated with structural changes of the heart like the extent 
of LV- hypertrophy and left atrial enlargement, reflecting 
adverse cardiac remodeling. Moreover, increasing quartiles 
of Endostatin were significantly associated with worsening 
diastolic function measured by tissue Doppler imaging 
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Control (n = 55) mild ALVDD (n = 169) HFpEF (n = 77)
Biomarker
Endostatin (ng/ml) 149.1 (130.6-176.9) 163.8 (145.4-191.3) 179.0 (159-220) < 0.001*
NT-pro-BNP (pg/ml) 90.1 (45.8-129.2) 86.7 (43.7-170.7) 343.6 (151.7-703.4) < 0.001*
Routine parameter
Total cholesterol (mg/dl) 189 (163-228) 193 (171-221) 191 (170-210) NS
LDL-cholesterol (mg/dl) 107 (89-135) 109 (89-135) 109 (86-129) NS
HDL-cholesterol (mg/dl) 53 (46-64) 50 (38-62) 48 (41-61) NS
Triclyceride (mg/dl) 119 (83-185) 142 (100-206) 131 (104-189) NS
Lp (a) (mg/dl) 8 (5-27) 18 (6-39) 15 (6-52) NS
TSH (mU/l) 1.20 (0.94-2.09) 1.42 (0.824-2.08) 1.315 (0.80-1.90) NS
Creatinine (mg/dl) 0.8 (0.7-0.9) 0.9 (0.7-0.9) 0.9 (0.75-1.10) NS
hsCRP 0.1 (0.1-0.3) 0.3 (0.1-0.6) 0.3 (0.2-0.69) 0.005*
Glucose 89 (84-97) 100 (91-111) 97 (89-103) 0.020*
Hb (mg/dl) 14.3 (13.3-15.1) 14.1 (13.2-15.0) 13.6 (12.5-14.5) 0.004*
CK (U/l) 76 (58-105) 78 (60-114) 72 (55-104) NS
SGOT (U/l) 25 (21-31) 25 (21-31) 26 (21-32) NS
LV geometry
IVS (mm) 10 (9-11) 12 (10-13) 12 (11-14) < 0.001*
PLW (mm) 10 (9-11) 12 (10-13) 12 (11-14) < 0.001*
LVEDD(mm) 44 (42-47) 44 (39-48) 45 (41-50) NS
LVESD (mm) 30 (28-34) 29 (25-34) 31 (27-36) NS
LVMi (g/m²) 72 (62-84) 81 (67-102) 91 (77-119) < 0.001*
Systolic function
EF (%) 68 (62-72) 67 (61-71) 67 (63-73) NS
Smax (cm/s) 7.2 (6.3-8.0) 6.3 (5.7-7.5) 6.1 (5.4-6.7) < 0.001*
Diastolic function
LA-Index (ml/m2) 25.4 (21.8-28.7) 29.8 (25.7-33.3) 39.3 (36.7-49.1) < 0.001*
E (cm/s) 60 (60-80) 60 (50-70) 80 (70-90) < 0.001*
A (cm/s) 60 (50-70) 80 (70-90) 80 (70-90) < 0.001*
E/A ratio 1.14 (0.68-1.25) 0.75 (0.67-0.86) 1.11 (0.85-1.25) < 0.001*
E´septal (cm/s) 8.4 (7.3-9.4) 5.9 (5.2-6.8) 5.4 (4.6-6.3) < 0.001*
E´lateral (cm/s) 10.7 (9.5-13.0) 8.2 (6.9-9.5) 6.9 (5.6-8.4) < 0.001*
Average E´(cm/s) 9.8 (8.6-11.0) 7.2 (6.1-8.1) 6.2 (5.2-7.2) < 0.001*
E/E´septal ratio 8.0 (6.9-9.0) 10.2 (8.3-11.9) 15.1 (12.5-17.1) < 0.001*
E/E´average ratio 7.0 (6.0-7.7) 8.4 (6.8-10.1) 13.3 (11.1-14.8) < 0.001*
*statistically significant (p < 0.05); NT-proBNP: N-terminal fragment of the prohormone B-type natriuretic peptide; LDL: low density lipoprotein; HDL: high density lipoprotein; 
Lp (a): lipoprotein (a); TSH: thyroid stimulating hormone; hsCRP: high sensitive C-reactive protein; Hb: hemoglobin; CK: creatinkinase; SGOT: serum glutamic oxaloacetic 
transaminase; IVS: interventricular septum; PLW: posterior lateral wall; LVEDD: left ventricular end-diastolic diameter; LVESD: left ventricular end-systolic diameter;  
EF: ejection fraction; LA: left atrial; E: early diastolic transmitral velocity; A: late diastolic transmitral velocity; E´: early diastolic tissue Doppler velocity; DF: diastolic function; 
LVDD: left ventricular diastolic dysfunction; HFpEF: heart failure with preserved ejection fraction; NS: non-significant. The Mann-Whitney U-test was used to analyze 
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Table 3 – Echocardiographic parameters stratified according to serum Endostatin quartiles. Values are median (interquartile range) or n (%). 
X2 test was used as appropriate
Parameter Endostatin 1rd quartile Endostatin 2nd quartile Endostatin 3rd quartile Endostatin 4th quartile p value
LV geometry
IVS (mm) 11 (9-12) 12 (11-13) 12 (11-13) 12 10-14) 0.032*
PLW (mm) 11 (10-13) 11 (10-13) 12 (10-13) 12 (10-14) NS
LVEDD (mm) 44 (41-47) 43 (40-47) 47 (40-49) 45 (40-48) NS
LEVSD (mm) 30 (27-34) 29 (26-32) 31 (27-35) 29 (24-37) NS
LVMi (g/m²) 76.4 (61.6-100.4) 74.2 (66.2-97.8) 87.8 (72.9-100.3) 94.5 (70.8-117.1) 0.024*
Systolic function
Ejection fraction (%) 65 (60-70) 68 (63-72) 67 (61-71) 69 (63-74) 0.029*
Smax (cm/s) 6.6 (5.8-7.7) 6.6 (5.8-7.7) 6.4 (5.6-7.2) 6.1 (5.3-7.0) 0.005*
Diastolic function
LA-Index (ml/m²) 28.6 (23.8-35.3) 31.2 (25.7-35.2) 29.9 (25.7-36.9) 33.4 (27.9-38.8) 0.023*
E (cm/s) 60 (50-75) 60 (50-70) 70 (50-80) 70 (60-80) NS
A (cm/s) 70 (60-80) 70 (60-80) 80 (70-90) 80 (70-95) < 0.001*
E/A ratio 0.9 (0.7-1.2) 0.9 (0.7-1.1) 0.8 (0.7-1.0) 0.8 (0.7-1.1) NS
E´septal (cm/s) 6.9 (5.6-8.0) 6.0 (5.3-7.3) 6.3 (5.3-7.3) 5.6 (4.9-6.2) < 0.001*
E´lateral (cm/s) 9.1 (7.1-10.7) 8.6 (7.0-10.2) 8.3 (7.0-10.2) 7.5 (6.3-8.9) 0.001*
Average E´ 7.9 (6.8-9.3) 7.4 (6.3-8.5) 7.6 (6.2-8.3) 6.4 (5.5-7.5 < 0.001*
E/E´septal ratio 8.8 (7.5-11.4) 10.3 (8.3-12.5) 10.8 (8.3-13.0) 12.1 (9.8-15.8) < 0.001*
E/E´average ratio 7.5 (6.5-9.8) 8.5 (7.1—10.5) 8.9 (7.1-11.5) 10.5 (8.4-13.1) < 0.001*
Laboratory
NT-pro-BNP (pg/ml) 81.40 (45.1-137.3) 93.25 (43.70-211.6) 104.6 (52.8-179.7) 218.2 (100.35-516.15) < 0.001*
*statistically significant (p < 0.05). IVS: interventricular septum; PLW: posterior lateral wall; LVEDD: left ventricular end-diastolic diameter; LVESD: left ventricular 
end-systolic diameter; EF: ejection fraction; LA: left atrial; E: early diastolic transmitral velocity; A: late diastolic transmitral velocity; E´: early diastolic tissue 
Doppler velocity; NT-proBNP: N-terminal fragment of the prohormone B-type natriuretic peptide; DF: diastolic function; LVDD: left ventricular diastolic dysfunction; 
NS: non-significant, HFpEF, heart failure with preserved ejection fraction. The Mann-Whitney U-test was used to analyze differences between the medians of two 
groups and the Kruskal-Wallis test to test the equality of medians among more than two distinct groups.
of Endostatin serum levels showed more advanced cardiac 
remodeling (LV hypertrophy and left atrial enlargement) as 
well as more severe diastolic function abnormalities reflecting 
increasing left ventricular filling pressures (Figure 1B). 
Consistently, there was a significant positive moderate 
correlation between Endostatin and NT-proBNP levels 
(r = 0.32, p < 0.001; Figure 1C).
Discussion
We hypothesized that circulating Endostatin levels are altered 
in patients with ALVDD and HFpEF. Furthermore, elevated 
levels are associated with the presence and severity of diastolic 
function abnormalities. To verify the hypothesis we performed a 
clinical observational study including 301 patients, which were 
assigned based on their echocardiographic characteristics to three 
different groups. To our knowledge, this is the first published report 
linking increased circulating Endostatin levels to the presence and 
severity of diastolic function abnormalities and HFpEF in a well 
phenotyped cohort of patients with normal systolic function. 
In the present study, Endostatin showed a graded increase from 
controls over ALVDD to HFpEF. Furthermore, higher Endostatin 
levels were significantly associated with established markers of 
structural cardiac abnormalities including the LAVi and increased 
LV mass as well as functional abnormalities like E/E’ ratio. 
Particularly, an increased LAVi without concomitant mitral valve 
disease reflects a chronic remodeling process typical for HFpEF.25 
Consistently, we found that elevated Endostatin levels were 
associated with elevated NT-proBNP levels, a well-recognized 
prognostic marker and indicator of elevated ventricular filling 
pressures among patients, independent from LVEF.26
Endostatin, a 20-kDa proteolytic fragment from the 
C-terminal domain of collagen XVIII, was shown to 
have an inhibitory effect on tumor growth working as an 
antiangiogenic growth factor.27 Endostatin plays a role 
in the local balance of angiogenesis and shows potent 
anti-angiogenic activity by inhibiting proliferation and 
migration of endothelial cells in addition to inducing 
endothelial cell apoptosis.27 Endostatin is produced by the 
proteolytic cleavage of the C-terminal domain of collagen 
XVIII, a component of the extracellular matrix. The precise 
mechanism of conversion from collagen XVIII to Endostatin 
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patients with coronary artery disease (CAD) demonstrate 
that Endostatin protein levels correlate significantly with 
reduced angiogenesis and poorly developed cardiac 
collateral vasculature.18,30
The results from our study fit well to the pathophysiological 
model used to explain the development of HFpEF. In general, 
HFpEF is a complex disease involving an interplay of various 
factors. There is the hypothesis that a failure of oxygen delivery 
to the cardiomycytes triggers a pro-angiogenic response in 
patients suffering from heart failure.31-33 Nonetheless, angiogenic 
and antiangiogenic growth factors often co-exist in tissues 
with angiogenesis.34 Thus, the status of endothelial cells and 
endothelial function is determined by a balance between these 
positive and negative factors on angiogenesis, and the balance 
may in inappropriate shifted towards antiangiogenic factors in 
patients with HF. It was shown that the role of microvascular 
dysfunction and microvascular inflammation is especial for 
patients with the diagnosis of HFpEF.5,35,36 A new pathophysiologic 
model presented by Redfield et al.8 points from pro-inflammatory 
coexisting conditions to systemic endothelial inflammation and 
impaired oxygen delivery.8 Global ventricular performance 
is highly dependent on oxygen supply and thus myocardial 
perfusion, and an essential component of myocardial perfusion 
during ventricular hypertrophy is the myocyte–microvascular 
balance and the myocyte/capillary ratio. In cardiac autopsy 
specimens, it has recently been shown that microvascular 
rarefaction is a downstream phenomenon in HFpEF.37 
Furthermore, Kitzman et al.38 has demonstrated that HFpEF 
patients display significant abnormalities in the skeletal muscle 
as well as an abnormal capillary-to-fiber ratio, probably building 
the basis for severe exercise intolerance in HFpEF patients.38 
In addition, Gouya et al.19 have shown in a relatively small HFrEF 
study population that high levels of serum Endostatin were 
associated with all-cause mortality and concluded that the effect 
of increased angiogenesis is HF may be blunted by an overspill of 
anti-angiogenic factors such as Endostatin.19 Thus, we hypothesize 
that similar pathophysiological concepts may be involved in 
patients with HFpEF, were a high proportion of patients has 
a coincidence of coronary artery disease and diabetes, both 
damaging the endothelial structure.39 This was also true for our 
patient population as shown in table 1. Endostatin could be 
moderator of the microvascular effects seen in these patients.40
Several limitations of this study must be acknowledged. 
The observational nature of the present study prohibits 
definitive determination of cause and effect relationships. 
Second, the present study was a single-center experience 
Figure 1 – (A) The boxplot graphics show serum Endostatin levels for the ALVDD, HFpEF patients and the control group. (B)The correlation between Endostatin levels and 
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